CADTH Canadian Drug Expert Committee recommendation: Esketamine (Spravato -- Janssen inc.) indication: for the treatment of major depressive disorder in adults
The CADTH Canadian Drug Expert Committee (CDEC) recommends that esketamine not be reimbursed for the treatment of MDD in adults. The results of two four-week randomized controlled trials (RCTs) (TRD3001 and TRD3002) and one randomized withdrawal study (TRD3003) did not demonstrate a consistent stati...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, December 2020
|
| Edition: | Version 1.0 Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that esketamine not be reimbursed for the treatment of MDD in adults. The results of two four-week randomized controlled trials (RCTs) (TRD3001 and TRD3002) and one randomized withdrawal study (TRD3003) did not demonstrate a consistent statistically significant benefit with esketamine in combination with a newly initiated oral antidepressant compared with placebo in combination with a newly initiated oral antidepressant, in the indicated population |
|---|---|
| Physical Description: | 1 PDF file (9 pages) |